Active, not recruitingPHASE1, PHASE2NCT03301168
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bellicum Pharmaceuticals
- Principal Investigator
- Bellicum PharmaceuticalsBellicum Pharmaceuticals, Inc.
- Intervention
- BPX-501 T cells(biological)
- Enrollment
- 120 enrolled
- Eligibility
- 26 years · All sexes
- Timeline
- 2014 – 2034
Study locations (10)
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Stanford University - Division of Pediatric Stem Cell Transplant & Regenerative Medicine, Palo Alto, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States
- Children's Hospital at Montefiore, The Bronx, New York, United States
- Oregon Health Sciences University - Doernbecher Children's Hospital, Portland, Oregon, United States
- University of Texas Southwestern-Children's Medical Center, Dallas, Texas, United States
- Baylor College of Medicine/ Texas Children's Hospital, Houston, Texas, United States
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03301168 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07328503CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07201974Virtual Reality for Post-Stroke Gait RehabilitationMcGill University